Vol. 5 No. 1 (2026)

Pakistan Journal of Medical & Cardiological Review

https://pakjmcr.com/index.php/1/about

Online ISSN 3007-2387

Print ISSN 3007-2379

Design and Synthesis of Novel Heterocyclic Compounds with Enhanced Antimicrobial Activity

Samiyah Tasleem
Alkawther University Karachi Email: samiyahtasleem2005@yahoo.com

Kamran Afzal
Basic science department, Majmaah University Email: K.ahamed@mu.edu.sa

Zil-E-Huma
Department of Chemistry, Ghazi University, Dera Ghazi Khan.
zilehuma41@gmail.com

Sohaib Usman
Department of Bioscience, COMSATS University Islamabad, Pakistan
Email: s.usman8@outlook.com

Author Details

Keywords: Antimicrobial Resistance, Heterocyclic Compounds, Benzimidazoles, Triazoles, Quinolines, Pharmacophore Modeling, QSAR, Molecular Docking, Microwave-Assisted Synthesis, Multicomponent Reactions, Green Chemistry, DNA Gyrase Inhibitors, Multi-Target Antimicrobials

Received on 10 Feb 2026
Accepted on 10 Mar 2026
Published on 20 Mar 2026

Corresponding E-mail & Author*:

Samiyah Tasleem
Alkawther University Karachi Email;
samiyahtasleem2005@yahoo.com

Abstract

The escalating crisis of antimicrobial resistance (AMR) poses a severe threat to global health, with projections estimating up to 10 million annual deaths by 2050 due to drug-resistant pathogens such as the ESCAPE group. This review explores the design and synthesis of novel heterocyclic compounds primarily nitrogen-containing scaffolds like benzimidazoles, triazoles, quinolines, and their hybrids as promising antimicrobial agents. These structures leverage pharmacophoric versatility, bioisosteric mimicry, and multi-targeting strategies to combat resistance mechanisms, including enzyme inactivation and efflux pumps. Key innovations include rational hybridization for broad-spectrum activity, computational tools (QSAR, pharmacophore modeling, molecular docking, and dynamics simulations) for predictive design, and sustainable synthetic methodologies (microwave-assisted organic synthesis, multicomponent reactions) emphasizing green chemistry principles. Benzimidazole derivatives exhibit tautomeric flexibility for enhanced enzyme binding, triazoles provide metabolic stability and linker functions via click chemistry, while quinoline hybrids target DNA gyrase and DHPS with MIC values as low as 1–5 μmol/mL. The integration of CADD accelerates lead optimization, with high statistical models ($R^2 > 0.95$) guiding anti-tubercular and antibacterial development. Overall, this work underscores the potential of heterocyclic chemistry to revitalize antimicrobial pipelines through efficient, eco-friendly synthesis and precise molecular engineering, offering a pathway to mitigate AMR.

Introduction

The global healthcare infrastructure is currently facing an existential threat from the rapid proliferation of antimicrobial resistance (AMR), a phenomenon that renders existing therapeutic regimens ineffective and jeopardizes the success of modern surgical and oncological interventions (Salam et al., 2023 The World Health Organization has classified AMR as one of the top ten global health threats, with projections suggesting that by 2050, drug-resistant infections could claim up to 10 million lives annually (Long, 2024). Central to this crisis is the emergence of the "ESCAPE" pathogens *Enterococcus faecium, Staphylococcus aureus, Clostridium difficile, Acinetobacter baumannii, Pseudomonas aeruginosa*, and *Enterobacteriaceae* which demonstrate a sophisticated repertoire of resistance mechanisms, including target site modifications, enzymatic drug inactivation, and hyperactive efflux pumps (Vrancianu et al., 2020).

In this landscape, heterocyclic chemistry has emerged as the most fertile ground for the design of novel antimicrobial agents. Heterocyclic compounds, defined by the presence of at least one heteroatom (typically nitrogen, oxygen, or sulfur) within a cyclic structure, account for more than 75% of all FDA-approved drugs (Kyriakidis et al., 2021). Their structural versatility allows for the precise modulation of electronic, steric, and lipophilic properties, enabling the design of molecules that can interact with diverse biological targets with high affinity and selectivity. Nitrogen-containing heterocycles, in particular, are vital scaffolds in medicinal chemistry due to their ability to form hydrogen bonds with amino acid residues in microbial enzymes, effectively acting as mimics or inhibitors of natural metabolites (Ibrahim et al., 2025).

The evolution of antimicrobial design has moved from empirical screening toward a rational, multi-targeted approach. This involves the hybridization of distinct pharmacophoric units into a single molecular entity to broaden the spectrum of activity and reduce the likelihood of resistance development (Kumar et al., 2020). For instance, combining a quinoline core with a triazole ring creates a hybrid molecule capable of targeting both DNA replication and metabolic pathways (Abu-Hashem & Al-Hussain, 2024). Furthermore, the transition toward green chemistry and non-conventional synthetic protocols, such as microwave-assisted and sonochemical methods, has streamlined the production of these complex architectures, emphasizing atom economy and environmental sustainability (Sivaraj et al., 2025). The global burden of antimicrobial resistance continues to escalate due to the rapid emergence of multidrug-resistant pathogens. Figure 1 illustrates the projected mortality associated with AMR and highlights the major ESCAPE pathogens responsible for hospital-acquired infections.



Figure 1: *Global Impact of Antimicrobial Resistance and ESCAPE Pathogens*

Structural Architecture and Pharmacophoric Versatility of Nitrogen Heterocycles

Nitrogen heterocycles dominate the antimicrobial landscape due to their resemblance to essential life components like purines, pyrimidines, and vitamins. The ability to functionalize these rings at multiple positions allows medicinal chemists to fine-tune their pharmacokinetic and pharmacodynamic profiles (Lungu et al., 2022).

Benzimidazoles: Isosteric Mimicry and Tautomeric Flexibility

The benzimidazole scaffold, consisting of a benzene ring fused to an imidazole ring, is a privileged structure that mimics the adenine and guanine bases of DNA. This structural similarity allows benzimidazole derivatives to interfere with microbial DNA processing (Beyer, 2025). A defining characteristic of the benzimidazole nucleus is its prototropic tautomerism, involving a rapid exchange of protons between the nitrogen atoms at the 1 and 3 positions (Lungu et al., 2021). This dynamic nature enables the molecule to adopt various orientations within the catalytic pockets of target enzymes, facilitating multiple hydrogen-bonding interactions (Zhao, 2025)

Recent research has focused on functionalization at the 2, 5, and 6 positions of the benzimidazole ring to enhance potency against multidrug-resistant (MDR) strains. For example, the introduction of bulky aromatic groups at the C2 position can improve hydrophobic interactions, while electron-withdrawing groups (EWGs) at the C5 position modulate the pK_a and metabolic stability of the compound (Chen et al., 2023). Benzimidazole hybrids, particularly those conjugated with triazoles or thiazoles, have shown exceptional activity against Gram-positive bacteria like MRSA by targeting the DNA gyrase B subunit (Xie et al., 2025).

Table 1. Key Modification Sites and Substituent Effects in Benzimidazole-Based Antimicrobials

Modification Site	Substituent Type	Biological Impact	Targeted Pathogen
C2 Position	Aromatic/Heterocyclic Hybrids	Enhanced hydrophobic binding	MRSA, *S. aureus* (Ibrahim et al., 2025)
C5/C6 Position	Electron-Withdrawing Groups (Cl, F, NO_2)	Improved metabolic stability	*P. aeruginosa* (Ibrahim et al., 2025)

N1 Position	Alkyl/Acyl groups	Solubility and membrane permeability	*E. coli* (Ibrahim et al., 2025)
Coordination Site	Metal Complexes (Ag, Zn, Cu)	Synergistic membrane disruption	MDR Bacterial Strains (Ibrahim et al., 2025)

Triazoles: Metabolic Stability and Bioisosteric Applications

Triazoles are five-membered rings containing three nitrogen atoms, occurring as 1, 2, 3- or 1,2,4-isomers. Their significance in drug design arises from their extreme stability toward oxidative and reductive conditions, as well as their resistance to enzymatic degradation (Kumari et al., 2020). The 1,2,4-triazole motif is particularly prevalent in antifungal agents like fluconazole and itraconazole, which act by inhibiting sterol 14-\alpha-demethylase (CYP51), thereby disrupting the synthesis of ergosterol in fungal cell membranes (Sindhushree et al., 2025).

An emerging trend in medicinal chemistry is the use of the triazole ring as a bioisostere for the carboxylic acid group or the amide bond. Unlike the carboxylate group, which is often metabolically labile and ionized at physiological pH, the triazole ring remains neutral and offers superior lipophilicity while retaining the ability to engage in hydrogen bonding (Atmaram et al., 2022). This bioisosteric replacement is frequently utilized to enhance the cellular uptake of antimicrobial leads. Furthermore, 1,2,3-triazoles, typically synthesized via "click chemistry" (CuAAC), serve as robust linkers in hybrid molecules, connecting quinoline or coumarin cores to auxiliary pharmacophores without interfering with their biological activity (Finamore et al., 2025).

Quinolines and Quinolinones: Legacy and Innovation

The quinoline scaffold remains a cornerstone of antimalarial and antibacterial therapy, exemplified by chloroquine and the fluoroquinolone class. Quinolines are characterized by their structural rigidity and favorable electronic charge transfer properties, which facilitate interactions with DNA and key metabolic enzymes like DNA gyrase and dihydropteroate synthase (DHPS) (Pradhan et al., 2023).

Innovations in quinoline chemistry involve the synthesis of fused systems, such as quinoline-pyrido[2,3-d]thiazolo[3,2-a]pyrimidines, which have demonstrated potent broad-spectrum activity. These complex heterocycles are designed to occupy multiple sub-pockets within the target enzyme, a strategy that mitigates the impact of single-point mutations in the pathogen (Azimi et al., 2025). Studies have shown that these derivatives can achieve MIC values as low as 1–5 \mumol/mL, rivaling standard antibiotics like cefotaxime sodium (El-Shershaby et al., 2021).

Computational Paradigms in Modern Antimicrobial Design

The transition from serendipitous drug discovery to rational design is underpinned by the integration of computer-aided drug design (CADD) modules. These tools allow for the systematic exploration of the chemical space and the prediction of biological activity before wet-lab synthesis (Rudrapal et al., 2020). The integration of computational techniques has revolutionized antimicrobial drug discovery. The typical workflow of computer-aided drug design used for heterocyclic lead optimization is summarized in Figure 2.



Figure 2: Computer-Aided Drug Design Workflow for Antimicrobial Heterocycles

Quantitative Structure-Activity Relationship (QSAR) and Pharmacophore Modeling

QSAR studies provide a mathematical framework to correlate chemical structure with biological activity, using molecular descriptors that capture electronic, hydrophobic, and steric properties (Shah et al., 2024). For example, in the development of anti-tubercular agents targeting the InhA and DprE1 enzymes of *Mycobacterium tuberculosis*, 3D-QSAR models have achieved high statistical significance, with R^2 values reaching 0.9521 and Q^2 values of 0.8589 (Mali et al., 2020). Such models reveal that the presence of electron-withdrawing groups and hydrophobic substitutions on the heterocyclic core are critical for maintaining potency against drug-resistant tuberculosis strains (Bastikar et al., 2022).

Complementing QSAR, pharmacophore modeling identifies the spatial arrangement of essential features required for biological activity. A six-point pharmacophore (AHHRRR) consisting of a hydrogen-bond acceptor, two hydrophobic groups, and three aromatic rings has been utilized to screen vast databases for novel anti-infectives (Vasilev et al., 2025). This targeted screening ensures that only the most promising candidates are synthesized, significantly reducing development costs and time (Achary, 2024).

Molecular Docking and Dynamics: Validating Target Engagement

Molecular docking simulates the binding of a ligand to the active site of a protein, providing insights into the orientation and energy of the interaction. For nitrogen-containing heterocycles, docking often highlights critical hydrogen bonds between the ring nitrogens and highly conserved amino acid residues, such as Lys721 in the EGFR pathway or Asp84 in the DHPS enzyme (Mahmoud et al., 2024).

However, static docking is often insufficient to capture the dynamic nature of protein-ligand complexes. Molecular dynamics (MD) simulations, often extending to 100–200 ns, are employed to assess the thermodynamic stability of the complex over time (Grewal et al., 2025). For instance, the screened compound MK3 showed stable binding with low root-mean-square deviation (RMSD) against both InhA and DprE1 targets, confirming its potential as a multi-targeted inhibitor (Jin et al., 2024). The analysis of binding free energy using MM-PBSA methods further quantifies the

affinity, with values reaching -71.3 kcal/mol for some quinolone-thiosemicarbazone hybrids (Valencia et al., 2023).

Table 2. Molecular Docking Results of Heterocyclic Derivatives Against Key Antimicrobial Target Enzymes

Target Enzyme	PDB ID	Software Utilized	Binding Energy (ΔG)	Interaction Type
DNA Gyrase	2XCT	AutoDock Vina	-8.90 kcal/mol	H-bonds, \pi-\pi stacking (Abu-Hashem & Al-Hussain, 2024)
DHPS	5U10	AutoDock	-11.70 kcal/mol	H-bonds, Pi-cation (Abu-Hashem & Al-Hussain, 2024)
InhA	2NSD	Schrödinger Phase	-9.2 kJ/mol	Hydrophobic, Ionic (Rudrapal et al., 2020)
EGFR	4CSV	MOE	-8.50 kcal/mol	Hydrogen bonding (Mahmoud et al., 2024)
DprE1	4FDO	GROMACS	-8.3 kJ/mol	Hydrophobic (Rudrapal et al., 2020)

Non-Conventional Synthetic Methodologies: Efficiency and Sustainability

The complexity of modern heterocyclic hybrids necessitates synthetic routes that are both efficient and environmentally responsible. Traditional batch synthesis is increasingly being replaced by microwave-assisted, multicomponent, and sonochemical protocols (Sivaraj et al., 2025).

Microwave-Assisted Organic Synthesis (MAOS)

Microwave irradiation provides a rapid and uniform heating mechanism, dramatically reducing reaction times from hours to minutes. This technique is particularly effective for high-pressure reactions and the synthesis of bioactive heterocycles like pyrroles, pyrazoles, and imidazoles (Starvaggi & Ettari, 2025). One study demonstrated that a heterocyclic synthesis requiring 290 minutes under conventional heating was completed in just 10–25 minutes under microwave radiation, with a significantly higher yield (97% vs 78%. Furthermore, the use of silicon-carbon (Si-C) vials allows for high-temperature resistance and selective heating, facilitating the use of heterogeneous catalysts (Jayant et al., 2025).

Multicomponent Reactions (MCRs) and Green Chemistry

MCRs allow for the construction of complex molecules from three or more components in a single step, minimizing waste and maximizing atom economy (Bosica et al., 2021). These reactions are highly valued for their ability to generate molecular diversity at multiple points. For example, the Ugi reaction has been successfully employed to synthesize N-heterocyclic peptoids with dual antibacterial and anticancer potential (Shen et al., 2025).

Green chemistry principles are further integrated through the use of environmentally benign solvents such as water, ionic liquids, or fresh fruit juices and metal-free catalytic systems (Messire et al., 2024). The oxidative C-H amination of benzoxazoles, traditionally requiring toxic transition metals, can now be achieved using hypervalent iodine or molecular iodine as catalysts, reducing the environmental footprint of pharmaceutical production (Grant et al., 2025).

Table 3. Comparison of Conventional, Microwave-Assisted, and Green Multicomponent Approaches for Heterocyclic Synthesis

Synthetic Parameter	Conventional Method	Microwave (MAOS)	MCR / Green Approach
Reaction Time	3–6 hours	10–25 minutes	Variable (step-efficient) (Sivaraj et al., 2025)
Solvent Requirement	Large volume organic	Solvent-free or Green	Water/Ionic Liquids (Ibrahim et al., 2025)
Product Yield	60–75%	85–98%	High Atom Economy (Sivaraj et al., 2025)
Catalyst	Heavy Metals	Heterogeneous/Metal-free	Biocatalysts/Hypervalent I (Ibrahim et al., 2025)

Advanced Hybridization Strategies: Expanding the Antimicrobial Spectrum

The fusion of two or more bioactive scaffolds into a single hybrid molecule is a powerful strategy to combat resistance and achieve synergistic effects. This approach targets multiple biochemical pathways, making it much harder for the pathogen to develop compensatory mutations (Ibrahim et al., 2025).

Ciprofloxacin-Azole Hybrids

Fluoroquinolones like ciprofloxacin are among the most effective antibiotics, but resistance is growing. By hybridizing the ciprofloxacin core with 1,3,4-oxadiazole or 1,2,4-triazole moieties at the C7-piperazine position, researchers have created molecules with enhanced potency (Shariati et al., 2022). These hybrids act as potent dual inhibitors of bacterial DNA gyrase and topoisomerase IV. For example, ciprofloxacin-oxadiazole hybrids demonstrated antibacterial activity ranging from 88% to 120% of the parent drug's efficacy, with IC_{50} values for DNA gyrase inhibition as low as 42 nM (Abu-Hashem & Al-Hussain, 2021).

Table 4. In Vitro Antimicrobial and Enzyme Inhibition Activity of Novel Hybrid Compounds Against DNA Gyrase, Topo IV, S. aureus, and E. coli

Hybrid Compound	IC50 DNA Gyrase	IC50 Topo IV	MIC S. aureus (µg/mL)	MIC E. coli (µg/mL)
Compound 4	42 nM	1.47 \muM	0.035	0.062 (Abu-Hashem & Al-Hussain, 2021)
Compound 3	86 nM	N/A	0.031	0.062 (Abu-Hashem & Al-Hussain, 2021)
Novobiocin	170 nM	11 \muM	N/A	N/A (Abu-Hashem & Al-Hussain, 2021)
Ciprofloxacin	Standard	Standard	0.030	0.008 (Abu-Hashem & Al-Hussain, 2021)

The structural elucidation of these hybrids via NMR and MS confirms that the methylene bridge connecting the piperazine and the oxadiazole ring is essential for maintaining the correct orientation within the enzyme's binding pocket (Peter, 2021). The SAR studies indicate that aromatic substitutions on the oxadiazole ring (e.g., 2-pyridyl or 2-naphthyl) are critical for enhancing the activity against *Pseudomonas aeruginosa* (Zang et al., 2022).

Coumarin-Thiazole and Thiazole-Triazole Hybrids

Coumarin and thiazole rings are both found in diverse natural products and exhibit broad-spectrum antimicrobial activity. Coumarin-tethered thiazoles have been designed to combat AMR by acting as multi-targeting agents (Belagali et al., 2024).

These hybrids not only inhibit DNA gyrase B but also induce the production of intracellular reactive oxygen species (ROS) (Peter & Sibali, 2025).
Compound 6c, a representative coumarin-thiazole hybrid, showed selective potency against *Enterococcus faecalis* (MIC: 12.5 \mug/mL) and *Achromobacter xylosoxidans* (MIC: 25 \mug/mL), values comparable to ciprofloxacin (Jain et al., 2026). Furthermore, these hybrids have demonstrated the ability to disrupt bacterial biofilms, a key defense mechanism of MDR pathogens that makes them hundreds of times more resistant to conventional antibiotics (Ebaid et al., 2025).

Overcoming Resistance: Mechanisms and Heterocyclic Countermeasures
The design of novel heterocycles must specifically address the evolving resistance mechanisms of pathogens. These include the modification of target enzymes, such as mutations in the DNA gyrase or sterol 14-\alpha-demethylase genes, and the expression of efflux pumps (Sindhushree et al., 2025).

DNA Gyrase and DHPS Inhibition
DNA gyrase is a primary target for quinolines and benzimidazoles. Resistance typically arises from mutations in the *gyrA* or *gyrB* subunits. Fused heterocyclic systems, such as quinoline-thiazolobenzimidazolone hybrids, are designed to engage with multiple residues in the enzyme, ensuring that a single mutation does not completely abolish drug binding (Long, 2024). In-silico screening of novel quinoline derivatives against DNA gyrase (PDB: 2XCT) has identified candidates with binding affinities superior to ciprofloxacin, particularly those forming H-bonds with Arg98 and Asp85 (Mohammed et al., 2023).
Similarly, dihydropteroate synthase (DHPS) is a key enzyme in the folate synthesis pathway. Quinolines and triazolopyrimidines have been shown to effectively inhibit DHPS by interacting with residues like Arg254 and Gly221 (Shamshad et al., 2020). Molecular docking of novel triazole-quinoline hybrids against the DHPS of *S. aureus* yielded significant binding energies (-8.90 kcal/mol), suggesting their potential to overcome sulfonamide resistance (Chawla er al., 2021).

Combating Fungal Resistance: The ERG11 Challenge
In fungal pathogens like *Candida auris* and *Aspergillus fumigatus*, resistance to triazoles is often mediated by mutations in the ERG11 gene, which encodes sterol 14-\alpha-demethylase (Qadri et al., 2024). To address this, researchers are developing triazole hybrids that utilize alternate binding modes or target secondary pathways, such as the disruption of intracellular ROS homeostasis (Hui et al., 2024). Some novel triazole-based polyaromatic compounds have demonstrated sub-micromolar activity (MIC: 0.35–0.63 \muM) against resistant *Saccharomyces cerevisiae* without inducing cytotoxicity in host cells (Jangir et al., 2025).

Pharmacokinetic and Toxicological Hurdles in Clinical Development
A critical challenge in the development of antimicrobial heterocycles is ensuring favorable pharmacokinetic properties and a high safety margin. Many potent antimicrobial leads fail in pre-clinical stages due to poor solubility, rapid metabolic clearance, or cardiotoxicity (Valencia et al., 2023).

Metabolic Stability and Half-Life Assessment
The hepatic metabolic stability of a lead compound determines its oral bioavailability and frequency of dosing. In-vitro assays using human and rat liver microsomes (HLM/RLM) are the industry standard for measuring metabolic turnover. Compounds are generally classified as unstable if their half-life 1/2 is less than 30 minutes (Ibrahim et al., 2025).

Recent advancements in computational modeling have allowed for the prediction of metabolic stability using machine learning techniques like Support Vector Machines (SVM). These models utilize structural data to accurately predict half-life values, facilitating the early identification of compounds that might suffer from high first-pass metabolism (Ozer et al., 2020). For example, pyrrolo[2,3-d]pyrimidine derivatives have been optimized to improve their stability, allowing them to act as effective antimetabolites with prolonged duration of action (Galal et al., 2022).

Cardiotoxicity and hERG Liability

One of the most common causes of drug attrition and withdrawal is the blockade of the hERG (human ether-à-go-go-related gene) potassium channel, which can lead to life-threatening cardiac arrhythmias (Su et al., 2021). Heterocyclic compounds, particularly those with lipophilic, polyaromatic, and basic amine characters, are frequently associated with hERG liability (Hoffmann et al., 2023).

To mitigate this risk, medicinal chemists employ strategies to reduce lipophilicity (ALogP) and increase the topological polar surface area (TPSA). Studies on piperazine and benzimidazole derivatives have shown that increasing molecular rigidity and lowering the pK_a of basic nitrogens can significantly reduce hERG binding affinity while maintaining antimicrobial potency (Kowalska et al., 2020). QSAR models for hERG inhibition now routinely guide the lead optimization process, ensuring that cardiotoxicity is addressed early in the development cycle (Kyro et al., 2025).

Table 5. Physicochemical Properties Influencing hERG Inhibition and Corresponding Optimization Strategies

Property	Relationship with hERG Inhibition	Optimization Strategy
Lipophilicity (ALogP)	Positive correlation	Decrease via hydrophilic groups (Sivaraj et al., 2025)
Basic Nitrogens	High pK_a increases risk	Lower basicity or incorporate into ring (Sivaraj et al., 2025)
Molecular Weight	Positive correlation	Maintain optimal drug-like size (Ibrahim et al., 2025; Sivaraj et al., 2025)
TPSA	Negative correlation	Increase polar surface area (Ibrahim et al., 2025; Sivaraj et al., 2025)
Flexibility	Rotatable bonds increase risk	Incorporate rigid scaffolds (Sivaraj et al., 2025)

Future Perspectives and Strategic Outlook

The future of antimicrobial drug discovery lies in the continued synergy between organic synthesis, computational biology, and innovative delivery systems. Heterocyclic chemistry will remain at the forefront, but with a growing emphasis on multi-targeted and "resistance-breaking" architectures (Salah, 2025).

Organometallic Hybrids and Nanotechnology

The integration of organometallic units, such as ferrocene or iridium complexes, into heterocyclic scaffolds represents a promising new frontier. These "metallo-antimicrobials" provide unique redox properties and structural motifs that are not available in purely organic compounds (Cunningham et al., 2020). For instance, quinoline-triazole hybrids with metal coordination have shown sub-micromolar activity against chloroquine-resistant malaria strains (Achary, 2024). Additionally, nanodelivery systems, such as nanoliposomal encapsulation, are being explored to improve the solubility and tissue targeting of heterocyclic leads, reducing systemic toxicity (Finamore et al., 2025).

Personalized Antimicrobial Therapy

As the cost of genomic sequencing decreases, the potential for personalized antimicrobial therapy grows. Heterocyclic libraries can be screened against the specific resistance profile of a patient's infection, allowing for the selection of the most effective hybrid agent (Jin et al., 2024). This approach, supported by rapid in-silico docking and AI-driven potency predictions, could revolutionize the treatment of chronic and life-threatening MDR infections (Pradhan et al., 2023).

Conclusions

In conclusion, the design and synthesis of novel heterocyclic compounds represent a pivotal strategy in addressing the global antimicrobial resistance crisis, where traditional therapies are increasingly ineffective against resilient pathogens like MRSA, P. aeruginosa, and M. tuberculosis. Nitrogen-rich scaffolds such as benzimidazoles, triazoles, and quinolines, along with their hybridized forms, offer unparalleled structural adaptability, enabling multi-modal interactions with microbial targets including DNA gyrase, DHPS, InhA, and CYP51. The synergy of computational paradigms QSAR for structure-activity correlations, pharmacophore screening for lead identification, and MD simulations for binding stability has transformed empirical approaches into predictive, cost-effective pipelines, achieving binding energies as low as -11.70 kcal/mol and robust statistical validations ($Q^2 > 0.85$). Complementing this, non-conventional synthetic routes like MAOS and MCRs promote sustainability by reducing reaction times, enhancing yields (up to 97%), and minimizing environmental impact through atom economy and catalyst-free conditions. Despite challenges such as off-target effects (e.g., hERG liability) and synthesis complexity, the integration of green chemistry, AI-driven optimization, and bioisosteric innovations positions these compounds as frontrunners for next-generation antimicrobials. Future efforts should focus on clinical translation, resistance profiling, and expanded hybrid libraries to ensure broad-spectrum efficacy and longevity, ultimately safeguarding public health in an era of evolving microbial threats.

References

Abu-Hashem, A. A., & Al-Hussain, S. A. (2021). A novel series of ciprofloxacin hybrids comprising various heterocycle derivatives. *Pharmaceuticals*, *14*(4), 399. https://doi.org/10.3390/ph14050399

Abu-Hashem, A. A., & Al-Hussain, S. A. (2024). Design, synthesis, antimicrobial activity, and molecular docking of novel thiazoles, pyrazoles, 1,3-thiazepinones, and 1,2,4-triazolopyrimidines derived from quinoline-pyrido[2,3-d] pyrimidinones. *Pharmaceuticals*, *17*(12), 1632. https://doi.org/10.3390/ph17121632

Beyer, A. (2025). Synthesis, computational analysis, and in vitro antimicrobial potential of amidoxime-based benzimidazole and benzimidamide derivatives. *Journal of Heterocyclic Chemistry*.

Ebaid, M. S., Farag, H., Abdelraof, M., Saleh, A. M., Thabit, M. G., Dziadek, J., Youssef, A. A., & Sabt, A. (2025). Design, synthesis, and biological assessment of a novel series of coumarin-tethered thiazole derivatives as potential antibacterial agents. *Frontiers in Chemistry*, *13*, 1627186. https://doi.org/10.3389/fchem.2025.1627186

Ibrahim, A. A., Said, E. G., AboulMagd, A. M., Amin, N. H., & Abdel-Rahman, H. M. (2025). Synthesis and SARs of benzimidazoles: Insights into antimicrobial innovation (2018–2024). *RSC Advances*, *15*, 22097–22115. https://doi.org/10.1039/D5RA00819K

Long, S. (2024). Emerging challenges in antimicrobial resistance: The role of ESCAPE pathogens. *Journal of Infectious Diseases*. https://pmc.ncbi.nlm.nih.gov/articles/PMC11622766/

Mahmoud, M., Maghraby, A., & Mostafa, A. (2024). Design, synthesis, and biological evaluation of a new series of benzimidazole/1,2,3-triazole hybrids as apoptotic antiproliferative agents that inhibit the EGFR pathway. *Frontiers in Chemistry*, *12*, 1541846. https://doi.org/10.3389/fchem.2024.1541846

Rudrapal, M., Chetia, D., & Singh, V. (2020). Atom-based 3D-QSAR, pharmacophore modeling and molecular docking studies of anti-tubercular agents. Journal of Drug Delivery & Therapeutics, 10(4), 225–233.

Sindhushree, S. R., Pradeep, S., Reddy, P., Achar, R. R., & Shivamallu, C. (2025). Novel triazino[4,3-a]quinolinecarboxylate compounds as potent antifungal agents against Candida species. *Chemical Biology & Drug Design*.

Sivaraj, N., Sakthivel, K., Kikushima, K., Kostić, M. D., Dohi, T., & Singh, F. V. (2025). Recent advances in non-conventional synthesis of N-heterocyclic compounds: Emerging strategies and biological perspectives. *RSC Advances*, *15*(42), 35509–35531. https://doi.org/10.1039/D5RA06028A

Valencia, J., Rubio, V., Puerto, G., Vasquez, L., Bernal, A., Mora, J. R., Cuesta, S. A., Paz, J. L., Insuasty, B., Abonia, R., Quiroga, J., Insuasty, A., Coneo, A., Vidal, O., Márquez, E., & Insuasty,

Salam, M. A., Al-Amin, M. Y., Salam, M. T., Pawar, J. S., Akhter, N., Rabaan, A. A., & Alqumber, M. A. (2023, July). Antimicrobial resistance: a growing serious threat for global public health. In Healthcare (Vol. 11, No. 13, p. 1946). MDPI.

Vrancianu, C. O., Gheorghe, I., Czobor, I. B., & Chifiriuc, M. C. (2020). Antibiotic resistance profiles, molecular mechanisms and innovative treatment strategies of Acinetobacter baumannii. Microorganisms, 8(6), 935.

Kyriakidis, I., Vasileiou, E., Pana, Z. D., & Tragiannidis, A. (2021). Acinetobacter baumannii antibiotic resistance mechanisms. Pathogens, 10(3), 373.

Kumar, H. M. S., Herrmann, L., & Tsogoeva, S. B. (2020). Structural hybridization as a facile approach to new drug candidates. Bioorganic & medicinal chemistry letters, 30(23), 127514.

Lungu, I. A., Moldovan, O. L., Biriș, V., & Rusu, A. (2022). Fluoroquinolones hybrid molecules as promising antibacterial agents in the fight against antibacterial resistance. Pharmaceutics, 14(8), 1749.

Zhao, P. (2025). Coordination Polymer Surface Chemistry and Enzyme Interaction Mechanisms: Molecular Recognition and Binding. Journal of Technology, Culture & Sustainability, 1(1), 1-10.

Chen, K. W., Sun, T. Y., & Wu, Y. D. (2023). New insights into the cooperativity and dynamics of dimeric enzymes. Chemical Reviews, 123(16), 9940-9981.

Xie, M., Du, J., Jia, M., Nie, X., Zhang, X., Hu, Y., & Nian, B. (2025). Computer-Aided Techniques in the Engineering of Enzyme Binding Pockets: New Perspectives and Frontiers. Journal of Agricultural and Food Chemistry, 73(33), 20600-20615.

Kumari, S., Carmona, A. V., Tiwari, A. K., & Trippier, P. C. (2020). Amide bond bioisosteres: Strategies, synthesis, and successes. Journal of medicinal chemistry, 63(21), 12290-12358.

Atmaram, U. A., & Roopan, S. M. (2022). Biological activity of oxadiazole and thiadiazole derivatives. Applied microbiology and biotechnology, 106(9), 3489-3505.

Finamore, C., Festa, C., Barbato, R., Fiorucci, S., Zampella, A., & De Marino, S. (2025). The Role of Five-Membered Aromatic Rings Containing N and O in Modulating Bile Acid Receptors: An Overview. ChemMedChem, 20(16), e202500405.

Pradhan, V., Kumar, R., Mazumder, A., Abdullah, M. M., Shahar Yar, M., Ahsan, M. J., & Ullah, Z. (2023). Molecular target interactions of quinoline derivatives as anticancer agents: A review. Chemical Biology & Drug Design, 101(4), 977-997.

Azimi, S. G., Shakour, N., Bagherzade, G., Saberi, M. R., Azimi, H., & Moosavi F, M. (2025). A comprehensive review of the biological activities of medicinal metal complexes synthesized from Quinoline scaffolds. Bioinorganic Chemistry and Applications, 2025(1), 3133615.

El-Shershaby, M. H., El-Gamal, K. M., Bayoumi, A. H., El-Adl, K., Alswah, M., Ahmed, H. E., ... & Abulkhair, H. S. (2021). The antimicrobial potential and pharmacokinetic profiles of novel quinoline-based scaffolds: synthesis and in silico mechanistic studies as dual DNA gyrase and DHFR inhibitors. New Journal of Chemistry, 45(31), 13986-14004.

Shah, M., Patel, M., Shah, M., Patel, M., & Prajapati, M. (2024). Computational transformation in drug discovery: A comprehensive study on molecular docking and quantitative structure activity relationship (QSAR). Intelligent Pharmacy, 2(5), 589-595.

Mali, S. N., Pandey, A., Thorat, B. R., & Lai, C. H. (2022). Multiple 3D-and 2D-quantitative structure–activity relationship models (QSAR), theoretical study and molecular modeling to identify structural requirements of imidazopyridine analogues as anti-infective agents against tuberculosis. Structural Chemistry, 33(3), 679-694.

Bastikar, V., Bastikar, A., & Gupta, P. (2022). Quantitative structure–activity relationship-based computational approaches. In Computational approaches for novel therapeutic and diagnostic designing to mitigate SARS-CoV-2 infection (pp. 191-205). Academic Press.

Mao, J., Akhtar, J., Zhang, X., Sun, L., Guan, S., Li, X., ... & Wang, G. (2021). Comprehensive strategies of machine-learning-based quantitative structure-activity relationship models. Iscience, 24(9).

Vasilev, B., & Atanasova, M. (2025). A (comprehensive) review of the application of quantitative structure–activity relationship (QSAR) in the prediction of new compounds with anti-breast cancer activity. Applied Sciences, 15(3), 1206.

Achary, P. G. (2020). Applications of quantitative structure-activity relationships (QSAR) based virtual screening in drug design: a review. Mini reviews in medicinal chemistry, 20(14), 1375-1388.

Grewal, S., Deswal, G., Grewal, A. S., & Guarve, K. (2025). Molecular dynamics simulations: Insights into protein and protein ligand interactions. In Advances in pharmacology (Vol. 103, pp. 139-162). Academic Press.

Jin, Z., & Wei, Z. (2024). Molecular simulation for food protein–ligand interactions: A comprehensive review on principles, current applications, and emerging trends. Comprehensive Reviews in Food Science and Food Safety, 23(1), e13280.

Starvaggi, J., & Ettari, R. (2025). Microwave-assisted organic synthesis: An eco-friendly method of green chemistry. Pharmaceuticals, 18(11), 1692.

Jayant, V., Kumar, R., Tyagi, P., & Yusuf, M. (2025). Microwave irradiation techniques. In Green Chemistry (pp. 67-96). Elsevier.

Bosica, G., Baldacchino, K., Abdilla, R., & De Nittis, R. (2021). Green organic synthesis via multicomponent reactions.

Shen, X., Hong, G., & Wang, L. (2025). Recent advances in green multi-component reactions for heterocyclic compound construction. Organic & Biomolecular Chemistry, 23(9), 2059-2078.

Messire, G., Caillet, E., & Berteina-Raboin, S. (2024). Green catalysts and/or green solvents for sustainable multi-component reactions. Catalysts, 14(9), 593.

Grant, A. (2025). Multi-component Reactions–Methods for Drug Discovery.

Shariati, A., Arshadi, M., Khosrojerdi, M. A., Abedinzadeh, M., Ganjalishahi, M., Maleki, A., ... & Khoshnood, S. (2022). The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic. Frontiers in public health, 10, 1025633.

Peter, S., & Aderibigbe, B. A. (2024). Ciprofloxacin and norfloxacin hybrid compounds: Potential anticancer agents. Current Topics in Medicinal Chemistry, 24(7), 644-665.

Zang, W., Li, D., Gao, L., Gao, S., Hao, P., & Bian, H. (2022). The antibacterial potential of ciprofloxacin hybrids against Staphylococcus aureus. Current Topics in Medicinal Chemistry, 22(12), 1020-1034.

Belagali, S. L., Bhat, M., & Joshi, B. K. (2024). Antimicrobial, anti-oxidant and anti-tubercular activity of coumarin tethered thiazole derivatives. ES General, 4, 1103.

Peter, S., & Sibali, L. L. (2025). Recent Developments on Coumarin Hybrids as Antimicrobial Agents. Antibiotics, 14(12), 1226.

Jain, A., & Paul, K. (2026). Multifaceted antibacterial action of dihydrofurocoumarins against drug-resistant Escherichia coli: biofilm inhibition, membrane disruption, metabolic dysfunction, and oxidative stress damage. Journal of Materials Chemistry B.

Mohammed, H. H., Ali, D. M. E., Badr, M., Habib, A. G., Mahmoud, A. M., Farhan, S. M., ... & Abuo-Rahma, G. E. D. A. (2023). Synthesis and molecular docking of new N 4-piperazinyl ciprofloxacin hybrids as antimicrobial DNA gyrase inhibitors. Molecular Diversity, 27(4), 1751-1765.

Shamshad, H., Bakri, R., & Mirza, A. Z. (2022). Dihydrofolate reductase, thymidylate synthase, and serine hydroxy methyltransferase: Successful targets against some infectious diseases. Molecular biology reports, 49(7), 6659-6691.

Chawla, P., Teli, G., Gill, R. K., & Narang, R. K. (2021). An insight into synthetic strategies and recent developments of dihydrofolate reductase inhibitors. ChemistrySelect, 6(43), 12101-12145.

Qadri, H., Mir, M. A., & Shah, A. H. (2024). Antifungal therapies and drug resistance. In Human fungal diseases (pp. 130-145). CRC Press.

Hui, S. T., Gifford, H., & Rhodes, J. (2024). Emerging antifungal resistance in fungal pathogens. Current clinical microbiology reports, 11(2), 43-50.

Jangir, P., Kalra, S., Tanwar, S., & Bari, V. K. (2023). Azole resistance in Candida auris: mechanisms and combinatorial therapy. Apmis, 131(8), 442-462.

Ozer, M. E., Sarica, P. O., & Arga, K. Y. (2020). New machine learning applications to accelerate personalized medicine in breast cancer: rise of the support vector machines. Omics: a journal of integrative biology, 24(5), 241-246.

Galal, A., Talal, M., & Moustafa, A. (2022). Applications of machine learning in metabolomics: Disease modeling and classification. Frontiers in genetics, 13, 1017340.

Su, S., Sun, J., Wang, Y., & Xu, Y. (2021). Cardiac hERG K+ channel as safety and pharmacological target. In Pharmacology of potassium channels (pp. 139-166). Cham: Springer International Publishing.

Hoffmann, P., & Pugsley, M. K. (2023). Assessing Cardiovascular Risk Beyond the hERG Channel and the QT Interval. In Current Topics in Nonclinical Drug Development (pp. 225-331). CRC Press.

Kowalska, M., Nowaczyk, J., & Nowaczyk, A. (2020). KV11. 1, NaV1. 5, and CaV1. 2 transporter proteins as antitarget for drug cardiotoxicity. International Journal of Molecular Sciences, 21(21), 8099.

Kyro, G. W., Martin, M. T., Watt, E. D., & Batista, V. S. (2025). CardioGenAI: a machine learning-based framework for re-engineering drugs for reduced hERG liability. Journal of Cheminformatics, 17(1), 30.

Salah, A. R. M. (2025). Heterocyclic Compounds in Modern Drug Design: Synthetic Strategies and Biological Targets.

Cunningham, L., Benson, A., & Guiry, P. J. (2020). Recent developments in the synthesis and applications of chiral ferrocene ligands and organocatalysts in asymmetric catalysis. Organic & Biomolecular Chemistry, 18(46), 9329-9370.